Summit Therapeutics (SMMT) Research & Development (2019 - 2026)
Summit Therapeutics (SMMT) posted Research & Development of $132.6 million for Q1 2026, down 9.96% on a QoQ basis from $147.3 million in Q4 2025, and up 158.69% year-over-year from $51.3 million in Q1 2025.
Summit Therapeutics (SMMT) Research & Development (2019 - 2026) Analysis & Trends
Summit Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $132.6 million for Q1 2026.
- Quarterly Research & Development rose 158.69% year-over-year to $132.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $619.0 million (up 261.65% YoY) and the FY2025 annual result came in at $537.7 million, up 256.6% from the prior year.
- Research & Development was $132.6 million for Q1 2026 at Summit Therapeutics, down from $147.3 million in the prior quarter.
- Across five years, Research & Development topped out at $208.0 million in Q2 2025 and bottomed at $5.4 million in Q4 2022.
- A 5-year average of $54.9 million and a median of $30.8 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development slumped 76.69% — and 2025, when it soared 575.44%.
- Summit Therapeutics' Research & Development stood at $5.4 million in 2022, then surged by 360.71% to $24.8 million in 2023, then jumped by 107.07% to $51.4 million in 2024, then jumped by 186.66% to $147.3 million in 2025, then dropped by 9.96% to $132.6 million in 2026.
- Business Quant data shows SMMT's Research & Development at $132.6 million in Q1 2026, $147.3 million in Q4 2025, and $131.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | -443.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 343.97 Mn |
| 10 | Summit Therapeutics | 10.60 Bn | 10.00 Bn | - | 132.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 132.62 Mn |
| Dec 31, 2025 | 147.29 Mn |
| Sep 30, 2025 | 131.10 Mn |
| Jun 30, 2025 | 208.02 Mn |
| Mar 31, 2025 | 51.27 Mn |
| Dec 31, 2024 | 51.38 Mn |
| Sep 30, 2024 | 37.72 Mn |
| Jun 30, 2024 | 30.80 Mn |
| Mar 31, 2024 | 30.87 Mn |
| Dec 31, 2023 | 24.81 Mn |
| Sep 30, 2023 | 15.32 Mn |
| Jun 30, 2023 | 9.45 Mn |
| Mar 31, 2023 | 9.88 Mn |
| Dec 31, 2022 | 5.39 Mn |
| Sep 30, 2022 | 17.05 Mn |
| Jun 30, 2022 | 9.01 Mn |
| Mar 31, 2022 | 20.56 Mn |
| Dec 31, 2021 | 23.11 Mn |
| Sep 30, 2021 | 19.94 Mn |
| Jun 30, 2021 | 23.92 Mn |